Ainos, Inc.AIMDEarnings & Financial Report
Ainos, Inc. is a biotechnology firm specializing in the development and commercialization of portable point-of-care diagnostic testing solutions. Its product portfolio includes infectious disease detection kits, hormone testing tools, and general health screening products, serving clinical, consumer, and public health segments across North America, Europe, and the Asia-Pacific.
AIMD Q1 FY2025 Key Financial Metrics
Revenue
$106.2K
Gross Profit
$88.0K
Operating Profit
$-3.2M
Net Profit
$-3.3M
Gross Margin
82.8%
Operating Margin
-2978.0%
Net Margin
-3094.0%
YoY Growth
412.4%
EPS
$-0.21
Ainos, Inc. Q1 FY2025 Financial Summary
Ainos, Inc. reported revenue of $106.2K (up 412.4% YoY) for Q1 FY2025, with a net profit of $-3.3M (up 0.9% YoY) (-3094.0% margin). Cost of goods sold was $18.2K, operating expenses totaled $3.3M.
Key Financial Metrics
| Total Revenue | $106.2K |
|---|---|
| Net Profit | $-3.3M |
| Gross Margin | 82.8% |
| Operating Margin | -2978.0% |
| Report Period | Q1 FY2025 |
Ainos, Inc. Quarterly Revenue & Net Profit History
Ainos, Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2025 | $106.2K | +412.4% | $-3.3M | -3094.0% |
| Q3 FY2024 | $0 | — | $-3.7M | N/A |
| Q2 FY2024 | $0 | — | $-3.2M | N/A |
| Q1 FY2024 | $20.7K | -57.8% | $-3.3M | -15991.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | |
|---|---|---|---|---|
| Revenue | $20729 | $0 | $0 | $106207 |
| YoY Growth | -57.8% | N/A | N/A | 412.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | |
|---|---|---|---|---|
| Assets | $29.8M | $35.5M | $31.4M | $26.4M |
| Liabilities | $7.1M | $14.8M | $13.3M | $13.2M |
| Equity | $22.7M | $20.7M | $18.0M | $13.1M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | |
|---|---|---|---|---|
| Operating CF | $-1.5M | $-2.0M | $-1.5M | $-1.2M |